Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3

Benzinga Newsdesk www.benzinga.com Negative 91.4%

Neg 91.4% Neu 0% Pos 0%

Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.